Ionis Pharmaceuticals, Inc. (LON:0JDI)

Market Cap	10.01B +131.2%
Revenue (ttm)	719.36M +20.4%
Net Income	-190.70M
EPS	-1.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,492
Average Volume	620
Open	84.51
Previous Close	83.27
Day's Range	81.67 - 84.97
52-Week Range	24.11 - 86.72
Beta	0.28
RSI	54.57
Earnings Date	Feb 18, 2026

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSE...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1989
• Employees: 1,069
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JDI

Financial Performance

In 2024, Ionis Pharmaceuticals's revenue was $705.14 million, a decrease of -10.48% compared to the previous year's $787.65 million. Losses were -$453.90 million, 23.9% more than in 2023.

Financial numbers in USD